Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Information About New Phase 1 Study Using CX-4945 In Relapsed/Refractory Multiple Myeloma Patients

Home/Information About New Phase 1 Study Using CX-4945 In Relapsed/Refractory Multiple Myeloma Patients

Information About New Phase 1 Study Using CX-4945 In Relapsed/Refractory Multiple Myeloma Patients

Here is a link to the Phase 1 clinical study I wrote about yesterday, featuring Cylene Pharmaceuticals’ CX-4945:

Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

The study is currently recruiting participants. Here are some highlights:

Purpose
This Phase 1 study of oral CX-4945 is designed to test the safety, tolerability, and highest safe dose level of this CK2 inhibitor in patients with relapsed or refractory multiple myeloma.

Eligibility

Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Criteria
Inclusion Criteria:

•Males or females at least 18 years of age
•Confirmed relapsed or refractory multiple myeloma after at least two prior lines of therapy.
•Measureable disease.
•Karnofsky Performance Status at least 60%
•Adequate liver and renal function and hematology laboratory values
•Female patients of child-bearing potential must have a negative pregnancy test.
•Signed informed consent.
Exclusion Criteria:

•Treatment with systemic cancer therapy within 21 days before screening.
•Major surgery within 4 weeks or minor surgery within 2 weeks of the start of study drug.
•Grade 3 sensory neuropathy or motor neuropathy with pain
•Concurrent severe or uncontrolled medical disease.
•Active systemic fungal, bacterial, and/or viral infection.
•Difficulty with swallowing, or an active malabsorption syndrome.
•Gastrointestinal diseases including Crohn’s disease or hemorrhagic coloproctitis.
•History of gastric or small bowel surgery.
•Pregnant or nursing females.

Locations
United States, Oregon
Oregon Health Science University Recruiting
Portland, Oregon, United States, 97239
Contact: Farnoush Abar, MD abarfa@ohsu.edu
Recruiting
Springfield, Oregon, United States, 97477
Contact: Jeanne Schaffer, RN jeanne.schaffer@usoncology.com
United States, South Carolina
Recruiting
Greenville, South Carolina, United States, 29605
Contact: Jan Kueber, RN jkueber@ghs.org
United States, Virginia
Recruiting
Norfolk, Virginia, United States, 23502
Contact: Gabrielle Geho, RN Gabrielle.Geho@usoncology.com

This is one of dozens of clinical trials which are currently seeking participants with multiple myeloma. This one is more experimental than most. There are certainly no guarantees of success. But if you are running out of options, you might consider getting involved.

Feel good and keep smiling! Pat